Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics Inc (SLNO) reports a strong initial market response to Vykat XR despite a significant net loss and high operational expenses in Q1 2025.

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as Vykat XR – to treat extreme hunger in patients with Prader-Willi ...

Diazoxide (as choline) 25mg, 75mg, 150mg; ext-rel tabs. <4yrs: not established. Swallow whole. Take with or without food once daily. ≥4yrs: (20–<30kg): Initially 25mg (Weeks 1 and 2), increase ...

Investing.com -- Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares gained 2.6% after the biopharmaceutical company provided an update on the U.S. launch of its newly approved drug VYKAT XR and reported ...

Soleno has established a comprehensive support program, Soleno ONE™, to assist patients, caregivers and healthcare providers ...

Prescriptions of VYKAT XR have now been delivered to the first individuals living with PWS who have been prescribed the medication. “We are extremely pleased to begin delivering VYKAT XR ...

Soleno Therapeutics (SLNO) announced the U.S. commercial availability of VYKAT XR extended-release tablets, the company’s treatment for hyperphagia in patients four years of age and older with ...